RecruitingNCT06822829

Multicenter Retrospective Observational Study of Relapsed Diffuse Large B-Cell Lymphoma Presenting as Indolent Lymphoma

Sponsor

Azienda USL Reggio Emilia - IRCCS

Enrollment

50 participants

Start Date

Aug 19, 2024

Study Type

OBSERVATIONAL

Conditions

Diffuse Large B-Cell Lymphoma (DLBCL)Indolent B-Cell Lymphomas Indolent B Cell Lymphoma

Summary

Most relapses of diffuse large B-cell lymphoma (DLBCL) occur as high-grade lymphoma within the first two years after diagnosis. Relapses as indolent lymphoma are rare events, and the true incidence of this phenomenon is unknown, since literature data are scarce/ and usually restricted to case reports. Analogously, reported treatment strategies are rather heterogeneous, since no standard of care is established and advanced age together with previous anthracycline exposure may narrow the therapeutic choice. The goal of this observational study is to assess epidemiological, clinical characteristics and survival of diffuse large b-cell lymphoma (DLBCL) relapsing as indolent lymphoma. More precisely, the study aims at identifying diagnostic and imaging features associated with relapse as indolent lymphoma and at evaluating disease response to selected therapies.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This observational retrospective study looks at patients who were first diagnosed with diffuse large B-cell lymphoma (DLBCL, an aggressive blood cancer) but later relapsed with a slow-growing (indolent) type of lymphoma. Researchers are collecting past records to understand outcomes and treatment patterns. **You may be eligible if...** - You are 18 or older - You were previously diagnosed with DLBCL and received first-line treatment for it - Your lymphoma later relapsed as a slow-growing (indolent) B-cell lymphoma, diagnosed between 2010 and 2020 - Complete medical records from both your original diagnosis and your relapse are available - You (or your next of kin, for deceased patients) have provided consent **You may NOT be eligible if...** - There are no specific exclusion criteria listed for this study Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.